Abstracts tagged "Myocardial involvement and myositis"

Abstract Number: 2976 • ACR/ARHP Annual Meeting 2018
Immune Checkpoint Inhibitor-Associated Myositis: A Characteristic Phenotype with a Poor Outcome Related to Concomitant Myocarditis
Celine Anquetil^1,2, Joe-Elie Salem^3,4, Benedicte Lebrun-Vignes⁵, Douglas B Johnson⁶, Andrew Mammen^7,8, Werner Stenzel⁹, Sarah Leonard-louis¹⁰, Olivier Benveniste^11,12, Javid J Moslehi³ and Yves Allenbach^2,13, ¹Internal Medicine and Clinical Immunlogy, Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, PARIS, France, ²CDR en myologie UMR974,, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, PARIS, France, ³Division of Cardiovascular Medicine and Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nasheville, TN, ⁴Department of Pharmacology, Regional Center of Pharmacovigilance, INSERM, CIC-1421, Paris, France, ⁵Department of Pharmacology, Regional Center of Pharmacovigilance, INSERM, CIC-1421, PARIS, France, ⁶Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nasheville, TN, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁸Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Charité - Universitätsmedizin, Department of Neuropathology, Berlin, Germany, Berlin, Germany, ¹⁰Département de Neuropathologie, Centre de Référence des Maladies Neuro-Musculaires Paris Est, Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Universitaire Pitié-Salpêtrière, Paris, France, ¹¹Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France, ¹²Centre de Recherche en Myologie, UMRS974, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Paris, France, ¹³Internal Medicine and Clinical Immunology, Sorbonne University - Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: Immune checkpoint inhibitors (ICI) are a major breakthrough in cancer treatment providing frequent durable responses and improving overall survival. Blocking immune checkpoints (Programmed cell…
Abstract Number: 1271 • ACR/ARHP Annual Meeting 2014
Myocarditis in Antisynthetase Syndrome
Céline Dieval¹, Olivier Benveniste², Christophe Deligny³, Alain Meyer⁴, Guillaume Lefevre⁵, Yoland Schoindre⁶, Aude Rigolet⁷ and Baptiste Hervier⁸, ¹Internal Medicine, Rochefort Hospital, Rochefort, France, ²UMR 974, Sorbonne Universités, University Pierre et Marie-Curie-Paris 6, INSERM, Paris, France, ³Internal Medicine, CHU Fort de France, Fort de France, France, ⁴Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ⁵Internal Medicine, CHRU Lille, Lille, France, ⁶DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, PARIS, France, ⁷Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, ⁸Internal Medicine & Clinical Immunology Dpt, Pitié-Salpêtrière Hospital, APHP, Paris, France
Background/Purpose Antisynthetase syndrome (aSS) corresponds to an overlapping inflammatory myopathy identified by different myositis specific autoantibodies (directed against tRNA-synthetases). Myocardial involvement in this condition is poorly…